Citations

Clear

127 citation(s) found for "Shari, G".

Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer
Poorvu, Philip D. , Gelber, Shari , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Lambertini, Matteo , Rosenberg, Shoshana M. , Ruddy, Kathryn J , Lambertini, Matteo , Partridge, Ann H , Zheng, Yue , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Cancer | December 1, 2020 | Volume: 127 | Issue: 7 | Pages: 1021-1028

10.1002/cncr.33342 | PMID 33259061 Get It

BackgroundMany young women with newly diagnosed breast cancer are interested in future pregnancies. Prospective data regarding fertility interest and reproductive patterns after diagnosis are needed to counsel patients.MethodsThe Young Women's Breast Cancer Study is a multicenter, prospective cohort of women who were diagnosed with breast cancer at age ≤40 years between 2006 and 2016. Women complete surveys at baseline, every 6 months for 3 years, then annually. Here, the authors describe fertility interest and pregnancies within 5 years of diagnosis for women with stage 0 through III breast cancer.ResultsOf 1026 eligible participants, 368 (36%) reported interest in future biologic children at least once within 5 years after diagnosis, including 16% at 5 years after diagnosis. Among 130 women who attempted to become pregnant, 90 (69.2%) conceived; and, among 896 women who did not attempt to conceive, 18 (2.0%) became pregnant, with a total of 152 pregnancies resulting in 91 live births. Factors associated with pregnancy included younger versus older age at diagnosis (aged ≤30 vs 36‐40 years: odds ratio [OR], 6.63; 95% CI, 3.18‐13.83; P < .0001; aged 31‐35 vs 36‐40 years: OR, 5.86; 95% CI, 3.37‐10.17; P < .0001) and being nulliparous versus parous (OR, 2.66; 95% CI, 1.56‐4.53; P = .001). The receipt of endocrine therapy versus no endocrine therapy (OR, 0.35; 95% CI, 0.20‐0.59; P = .001) was inversely associated with pregnancy.ConclusionsMany women remain interested in future fertility in the 4 years after a breast cancer diagnosis, indicating that longitudinal fertility discussions are needed. Although a minority of those interested in having children attempted to become pregnant in the first 5 years, most who attempted to conceive did so and had live births.
616 A novel non-covalent linker peptide with nanomolar affinity for clinical IgG1 antibodies preserves antibody-antigen affinity and drug potency against PDL1+ melanoma when conjugated with DM1
Butterfield, John T. , Sutor, Shari L., Nevala, Wendy N., Markovic, Svetomir, Markovic, Svetomir N.

Mayo Clinic

Regular and young investigator award abstracts | November 9, 2020 | Volume: No volume available | Issue: No issue available | Pages: A370-A371

10.1136/jitc-2020-sitc2020.0616 Get It

Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation
Becher, Laura , Nevala, Wendy K. , Sutor, Shari L., Abergel, Megan , Hoffmann, Michele M., Parks, Christopher A. , Pease, Larry R. , Schrum, Adam G. , Gil, Diana , Becher, Laura R E, Sutor, Shari Lee, Schrum, Adam G , Markovic, Svetomir N.

Mayo Clinic

Blood Advances | October 30, 2020 | Volume: 4 | Issue: 21 | Pages: 5343-5356

10.1182/bloodadvances.2020002255 | PMID 33125463 Get It

Abstract Human cytomegalovirus (HCMV) induces long-lasting T-cell immune responses that control but do not clear infection. Typical responses involve private T-cell clones, expressing T-cell antigen receptors (TCRs) unique to a person, and public T-cell clones with identical TCRs active in different people. Here, we report the development of a pretherapeutic immunostimulation modality against HCMV for human T cells, CD3 copotentiation, and the clonal analysis of its effects in recall assays at single-cell resolution. CD3 copotentiation of human T cells required identification of an intrinsically inert anti-CD3 Fab fragment that conditionally augmented signaling only when TCR was coengaged with antigen. When applied in recall assays, CD3 copotentiation enhanced the expansion of both public and private T-cell clones responding to autologous HLA-A2(+) antigen-presenting cells and immunodominant NLVPMVATV (NLV) peptide from HCMV pp65 protein. Interestingly, public vs private TCR expression was associated with distinct clonal expansion signatures in response to recall stimulus. This implied that besides possible differences in their generation and selection in an immune response, public and private T cells may respond differently to pharmacoimmunomodulation. Furthermore, a third clonal expansion profile was observed upon CD3 copotentiation of T-cell clones from HLA-A2(−) donors and 1 HLA-A2(+) presumed-uninfected donor, where NLV was of low intrinsic potency. We conclude that human T-cell copotentiation can increase the expansion of different classes of T-cell clones responding to recall antigens of different strengths, and this may be exploitable for therapeutic development against chronic, persistent infections such as HCMV.
S0468 Virtual Patient Simulation Improves IBS Diagnosis and Treatment: A CME Study
Lubarda, Jovana, Dermer, Shari, Lacy, Brian E. , Brenner, Darren M. , Lacy, Brian E.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S235-S235

10.14309/01.ajg.0000703920.81985.d7 Get It

Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health
Borstelmann, Nancy A. , Rosenberg, Shoshana M. , Gelber, Shari , Zheng, Yue , Meyer, M. M.M.M.D.E., Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Cadet, Tamara , Maramaldi, Peter , Rosenberg, Shoshana , Cadet, Tamara , Maramaldi, Peter , Partridge, Ann H , Zheng, Yue , Meyer, Meghan E., Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Journal of Psychosocial Oncology | October 1, 2020 | Volume: 38 | Issue: 6 | Pages: 670-686

10.1080/07347332.2020.1823546 | PMID 33000705 Get It

Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors
Rosenberg, Shoshana M. , Dominici, Laura S. , Gelber, Shari , Poorvu, Philip D. , Ruddy, Kathryn J. , Wong, Julia S., Schapira, Lidia , Come, Steven E. , Peppercorn, Jeffrey , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

JAMA Surgery | September 16, 2020 | Volume: 155 | Issue: 11 | Pages: 1035

10.1001/jamasurg.2020.3325 | PMID 32936216 Get It

Posttraumatic stress in breast cancer survivors diagnosed at a young age
Vazquez, Danny, Rosenberg, Shoshana M. , Gelber, Shari , Ruddy, Kathryn J. , Morgan, Evan , Recklitis, Christopher J. , Come, Steven E. , Schapira, Lidia , Partridge, Ann H. , Rosenberg, Shoshana , Recklitis, Christopher , Partridge, Ann H

Mayo Clinic

Psycho-Oncology | June 9, 2020 | Volume: 29 | Issue: 8 | Pages: 1312-1320

10.1002/pon.5438 | PMID 32515073 Get It

AbstractObjectiveYoung breast cancer patients experience greater psychosocial distress compared with older patients, which raises concern for their risk of posttraumatic stress disorder (PTSD). We sought to characterize the prevalence of clinically significant symptoms of PTSD and associated factors among breast cancer survivors diagnosed at a young age.MethodsThe Young Women's Breast Cancer Study, an ongoing prospective cohort study, enrolled 1302 women diagnosed with breast cancer at age ≤ 40 between 2006 and 2016. Participants complete serial surveys, and we obtained additional information from medical record review. Socio‐demographics, anxiety and depression, social support, and psychiatric co‐morbidities and medications were assessed at study baseline (median, 5 months post‐diagnosis). We defined a participant as having clinically significant posttraumatic stress symptoms (PTSS) by scoring ≥50 on the PTSD Checklist‐Specific Version, administered on the 30‐month survey.ResultsAmong 700 women with stage 1‐3 disease, the prevalence of PTSS was 6.3% (95%CI = 4.5‐8.1). In multivariable analyses, PTSS was significantly associated with anxiety (OR 12.43, 95%CI = 5.81‐26.59, P < .0001) and stage 2 vs 1 disease (OR 2.26, 95%CI = 1.04‐4.93, P = .04). PTSS was inversely associated with having a college degree (OR 0.29, 95%CI = 0.13‐0.62, P = .002) and greater social support (OR 0.44, 95%CI = 0.21‐0.94, P = .03).ConclusionsWe found similar rates of cancer‐related PTSS in breast cancer survivors diagnosed at a young age compared with the general breast cancer population despite their well‐documented increased risk of overall distress. Nevertheless, factors associated with posttraumatic stress should be considered at diagnosis and in survivorship to identify young patients who may benefit from psychosocial resources.
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Bean, Sarah , Bradley, Kristin , Campos, Susana M. , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Han, Ernest , Huh, Warner K. , Lurain, John R., Mariani, Andrea , Nagel, Christa , Nekhlyudov, Larissa , Fader, Amanda N. , Remmenga, Steven W., Reynolds, R. Kevin, Sisodia, Rachel , Tillmanns, Todd , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Motter, Angela D., Chu, Christina , Cohn, David E. , Crispens, Marta Ann , Mutch, David G.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 5, 2020 | Volume: 18 | Issue: 6 | Pages: 660-666

10.6004/jnccn.2020.0027 | PMID 32502976 Get It

The NCCN Guidelines for Cervical Cancer provide recommendations for diagnostic workup, staging, and treatment of patients with the disease. These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to first- and second-line systemic therapy recommendations for patients with recurrent or metastatic disease, and emerging evidence on a new histopathologic classification system for HPV-related endocervical adenocarcinoma.
Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.
Sella, Tal , Gelber, Shari , Poorvu, Philip D. , Kim, Hee Jeong , Arocho, Yaileen D Guzman, Collins, Laura C. , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Russell, Christy , Rosenberg, Shoshana M. , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Snow, Craig , Jakubowski, Debbie , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 514-514

10.1200/jco.2020.38.15_suppl.514 Get It

514 Background: The 21- gene Breast Recurrence Score predicts benefit from adjuvant chemotherapy in estrogen receptor positive (ER+), HER-2 negative (-) breast cancer (BC). We aimed to examine whether the 21-gene assay predicts response to neoadjuvant chemotherapy (NAC). Methods: We identified patients with stage I-III ER+/HER2− BC treated with NAC from the Young Women's Breast Cancer Study, a prospective cohort of women diagnosed with BC at age ≤ 40 years. The 21-gene assay was performed on tumor specimens removed prior to NAC either as part of clinical care or retrospectively for research. Pathologic complete response (pCR) was defined as no residual invasive tumor (ypT0/is ypN0). The relationship between Recurrence Score result (RS) and pCR was evaluated using logistic regression modeling. Results: 76 women in the cohort had undergone NAC for ER+, HER2- BC and were eligible for this analysis: 5 had undergone clinical 21-gene assay testing, 71 had banked specimens retrospectively tested. Median age at diagnosis was 36.7 (24.3-40). Most tumors were of ductal histology (78%), high grade (51%), progesterone receptor (PgR) positive (86%), ≥T2 (88%), clinically node positive (74%), and anthracycline and taxane containing protocols were administered in 86% of cases. RS ranged between 5-75 with 50% > 25 and only 4 < 11. Mean RS was significantly higher among tumors achieving pCR vs. non-pCR response (51.9 vs. 26.6, pwilcoxon= 0.0005). pCR rate in patients with RS > 25 was 21% (8/38) vs. 5% in patients with RS < 25 (2/38), with both pCRs in the <25 group in patients with RS 21-25. In univariable analysis, PgR negativity (odds ratio (OR) 5.62, 95% confidence interval (CI) 1.27-24.89, p = 0.02), high grade (OR 9.03, 95%CI 1.07-76.32, p = 0.04) and higher RS as a continuous variable (OR 1.08, 95%CI 1.04-1.13, p = 0.0003) were associated with a greater likelihood of pCR. In multivariable analysis only RS remained significantly associated with pCR (OR: 1.07, 95%CI 1.01-1.12, p = 0.01): a 7% increase in the odds of pCR for every 1-point increase in RS. Conclusions: In young women with ER+, HER2- BC who received NAC, higher pretreatment RS was associated with an increased likelihood of pCR. Genomic expression profiling assays may have a role in decision-making in young women in need of neoadjuvant therapy. For women with low likelihood of benefiting from NAC, alternative approaches are clearly warranted. Given the demonstrated efficacy of neoadjuvant endocrine therapy in post-menopausal women, further evaluation in young women should be pursued.
Risk of Recurrence and 10-Year Outcomes in Surgically Treated Nonmelanoma Skin Cancer in Cardiac and Liver Transplant Recipients
Yu, Nathan Y. , DeWees, T.A. , Alam, Mustafa , Ochoa, Shari A. , Mangold, Aaron R. , Steidley, D. Eric , Vargas, Hugo E. , Golafshar, Michael A. , Halyard, Michele Y. , Patel, Samir H. , Mangold, A R , Vargas, Hugo E , DeWees, Todd A , Golafshar, Michael , Schild, Steven E.

Mayo Clinic

American Journal of Clinical Oncology | March 26, 2020 | Volume: 43 | Issue: 5 | Pages: 366-370

10.1097/coc.0000000000000677 | PMID 32217856 Get It

Objectives: To report long-term outcomes of nonmelanoma skin cancer (NMSC) in immunosuppressed cardiac and liver transplant recipients (CLTR). Materials and Methods: The authors reviewed CLTR at the Mayo Clinic in Arizona from 1986 to 2013. Patient and tumor characteristics were recorded. Survival rates were calculated using the Kaplan-Meier method. Patient-specific and lesion-specific analyses were performed. Univariate and multivariate cox regressions were performed for comparisons. Results: Seven-hundred and forty-seven patients underwent cardiac (138) or liver (609) transplantation and of these, 97 patients (13%) developed 382 invasive NMSC. The median follow-up was 11 (range, 3 to 27) years for surviving patients. Primary treatment was mainly surgery alone. At 10 years, the local recurrence (LR) rate was 20% (95% confidence interval, 15%-28%), and 14% of patients had multiple LRs. At 10 years, LR rates were higher for T3/T4 tumors when compared with T1/T2 tumors (32.5% vs. 20%, P=0.05). At 10 years, overall survival was 79% (95% confidence interval, 64%-88%). On multivariate analysis, age 61 years and more demonstrated inferior overall survival (P<0.01). Conclusions: This is the first study describing the AJCC 8th edition stage-based patterns of recurrence and long-term outcomes of surgically managed NMSC in a large cohort of immunosuppressed CLTRs. T3 and T4 tumors recur more often than early stage tumors. Further study is required to identify factors related to recurrence and guide upfront treatment intensification in this high-risk population.